Clinical TrialJul 30, 2026, 08:08 AM
Evommune Initiates Phase 2b Trial for Migraine Drug EVO756
AI Summary
Evommune, Inc. announced the initiation of a Phase 2b clinical trial for its MRGPRX2 inhibitor, EVO756, for the prophylactic treatment of migraine. The trial will enroll approximately 330 adult patients with refractory migraine, evaluating daily doses up to 100 mg over 12 weeks. EVO756 is designed to inhibit three key neuropeptides involved in migraine, with top-line data expected in 2027.
Key Highlights
- Evommune initiated a Phase 2b clinical trial for EVO756 in migraine prophylaxis.
- EVO756 is an oral MRGPRX2 inhibitor targeting trigeminal neurons and mast cells.
- It is designed to inhibit PACAP, VIP, and Substance P neuropeptides.
- The trial will enroll approximately 330 patients with refractory migraine.
- Patients will receive daily doses up to 100 mg over 12 weeks.
- The primary endpoint is the mean change in monthly migraine days (MMD).
- Top-line data from the trial is anticipated in 2027.
Price Impact
More from EVMN